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Abstract
Background
Serum creatine kinase (sCK) reflects CK activity from striated skeletal muscle. Muscle wast-
ing is a risk factor for mortality in patients with chronic kidney disease (CKD). The aim of this
study is to evaluate whether sCK is a predictor of mortality and end-stage renal disease
(ESRD) in a CKD population.
Methods
We included 1801 non-dialysis-dependent CKD patients from the NephroTest cohort. We
used time-fixed and time-dependent cause-specific Cox models to estimate hazard ratios
(HRs) for the risk of death and for the risk of ESRD associated with gender-specific sCK
tertiles.
Results
Higher sCK level at baseline was associated with a lower age, a higher body mass index,
and a higher level of 24 h urinary creatinine excretion, serum albumin and prealbumin
(p<0.001). Men, patients of sub-Saharan ancestry, smokers and statin users also experi-
enced a higher level of sCK. In a time-fixed Cox survival model (median follow-up 6.0
years), the lowest gender-specific sCK tertile was associated with a higher risk of death
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before and after adjustment for confounders (Crude model: hazard ratio (HR) 1.77 (95% CI:
1.34–2.32) compared to the highest tertile; fully-adjusted model: HR 1.37 (95% CI: 1.02–
1.86)). Similar results were obtained with a time-dependent Cox model. The sCK level was
not associated with the risk of ESRD.
Conclusion
A low level of sCK is associated with an increased risk of death in a CKD population. sCK
levels might reflect muscle mass and nutritional status.
Introduction
Creatine kinase (CK), also referred to as creatine phosphokinase (CPK), is a cytosolic and mito-
chondrial enzyme that catalyzes the phosphorylation of creatine into phospho-creatinine, a rap-
idly mobilizable reserve of high energy phosphates: phosphocreatine donates a phosphate group
to adenosine diphosphate (ADP) to generate adenosine triphosphate (ATP). CK is an important
enzyme in tissues that consumes ATP rapidly, including the muscles and brain [1], and serum
CK (sCK) activity measurement is used as a blood test to monitor damage in CK-rich tissues,
mainly in striated muscles [2]. sCK activity is currently measured in clinical practice to detect
and monitor muscle-associated diseases, including rhabdomyolysis, myocardial infarction,
myositis and muscle dystrophy. Beside its diagnostic value of tissue damage, the sCK level yields
prognostic value because high blood concentrations of sCK have been associated with increased
mortality during rhabdomyolysis [3], traumatic injuries [4], viral infections (for example hanta-
viruses [5]), and genetic myopathies [6]. In a population of hospitalized, elderly patients, the
1-year mortality rate was high (27%) [7] in individuals with a sCK> 1000 UI/l. A moderately
elevated level of sCK was also shown to be associated with an increased risk of high blood pres-
sure [8]. Little is known, however, about its potential role as a marker in muscle wasting.
Muscle wasting is a known risk factor for mortality in dialysis patients [9,10] and occurs
early in the history of chronic kidney disease (CKD) [11]. Several studies have associated various
biomarkers with muscle mass, including daily urinary creatinine excretion (UCr) [12–14], and a
low UCr is associated with increased mortality in CKD patients [15,16]. A limitation to the rou-
tine use of UCr in clinical practice is that it requires adequate (neither incomplete nor excessive)
24-h urine collection. Evidence indicates that sCK reflects muscular mass. Indeed, the sCK level
is higher in healthy men compared to women [17] and in black individuals compared to Cauca-
sians [18]. sCK has been associated with muscle mass in studies comparing athletes to the gen-
eral population [19], as well as with body mass index (BMI) [20] and lean body mass [21].
Whether sCK may be a prognostic tool in CKD is currently unknown. To address this ques-
tion, we undertook a longitudinal population-based observational study on 1801 CKD patients
(the NephroTest study) to determine if sCK is associated with the risk of mortality and end
stage renal disease (ESRD).
Materials and Methods
Study population
The NephroTest study is a multicentric, hospital-based prospective cohort that enrolled 2084
non-ESRD adult patients  18 years of age between January 2000 and December 2012 with all
kidney disease types and all stages of CKD. Patients were enrolled upon discovery of CKD and
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all patients were referred for GFR measurement at the discretion of the nephrologist. Pregnant
women and kidney transplant recipients were excluded. From the initial cohort, 37 patients
missed the baseline measurement for sCK levels, and 138 patients were lost to follow-up.
Ninety-six (96) patients with a baseline-measured glomerular filtration rate (mGFR) lower
than 15 ml/min were excluded. In general, an sCK level>5 times its normal value is accepted
by many authors as a diagnostic criteria for rhabdomyolysis [22,23]. Twelve (12) individuals
(<1%) with an sCK level> 5 times its normal value (sCK> 855 UI/l in men and> 725 UI/l in
women, normal ranges<171 UI/L in males and<145 UI/l in females) were excluded to elimi-
nate cases of patent rhabdomyolysis. Consequently, 1801 patients were included in the present
analysis (Fig 1).
Data collection and outcome
Data at baseline and at each follow-up visit were recorded during a 5-hour in-person visit,
which consisted in the collection of a large set of clinical and laboratory indicators, including
blood pressure measurement, body mass index (BMI), relevant medical history and treatments
received. Follow-up was conducted through December 31, 2013; patients were referred for fol-
low-up GFR measurement at the discretion of their physician, these follow-up visits were not
mandatory. Follow-up information concerning vital status was obtained by a linkage with the
Fig 1. Study flowchart.
doi:10.1371/journal.pone.0156433.g001
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national death registry. ESRD were collected through medical records and from the French
REIN Registry. ESRD was defined by dialysis or preemptive kidney transplantation. All sur-
vival data were censored on December 31, 2013 for patients identified from ESRD or death reg-
istries or to the date of the last visit.
Clinical chemistry
Renal clearance of 51Cr-EDTA was used to measure GFR at enrollment and each visit, as previ-
ously described [24]. In short, a single dose of 1.8–3.5 MBq of 51Cr-EDTA (GE Healthcare,
Vélizy, France) was injected, and one hour later, the average renal 51Cr-EDTA clearance was
determined for five to six consecutive 30-minute clearance periods.
The quantitative determination of CK (CK-Nac) is performed using the kinetic measurement
of absorbance at 340/660 nm due to the formation of nicotinamide adenine dinucleotide phos-
phate (NADPH), which is directly proportional to the activity of CK in the sample of human
serum. CK-Nac is a modification of the International Federation of Clinical Chemistry (IFCC)
methods for the measurements of catalytic concentration of enzymes [25] performed on Beck-
man Coulter analyzers. Normal ranges are<171 UI/L in males and<145 UI/l in females.
Because a 24-h urine collection may be inaccurate, we made the assumption that a UCr is
stable over 24 hours and used a 24-h UCr extrapolated from fractionated creatinine clearance,
as described previously [15,26].
Statistical analysis
Variables were expressed as percentages or medians (interquartile range, IQR). Associations
between the baseline sCK level and the covariables were established by comparing 3 groups,
defined by their sCK value and expressed as gender-specific tertiles. Comparisons between
groups were made using the Kruskal-Wallis test for quantitative covariables and Pearson’s chi-
square test for qualitative covariables. Associations between the baseline sCK level were treated
as a continuous variable, and the covariables were established as follows: for quantitative mea-
surements, we used Pearson’s correlation coefficients to assess the correlation between the sCK
level and continuous variables; for qualitative measurements, we used the Wilcoxon or Krus-
kal-Wallis tests when appropriate.
To assess the impact of baseline sCK level on the risk of death, the risk of death before
ESRD or of ESRD, we conducted cause-specific Cox regression analyses to estimate crude and
cause-specific adjusted hazard ratio (HRs) and 95% confidence intervals, with the highest sCK
tertile as the reference category. Five nested models allowed for successive adjustment on the
following: (1) demographic characteristics (gender, age, ethnicity, medical center), (2) con-
founding factors (statin intake, ASAT level), (3) mGFR, (4) cardiovascular and renal risk fac-
tors (i.e., diabetes, smoking status, systolic blood pressure, history of cardiovascular events,
type of nephropathy, logarithm of proteinuria/creatinuria ratio) and finally, (5) markers of
nutritional status (BMI, albumin, prealbumin, 24-h creatinuria). Adjusted model 3 was also
run with mGFR replaced by GFR estimated (eGFR) using an adjusted CKD-EPI equation [27].
To estimate mortality and ESRD HRs associated with sCK levels during follow-up, we also per-
formed time-dependent Cox models with adjustment covariates similar to the time-fixed mod-
els. Subsidiary analyses were performed on sCK treated as a continuous variable. Proportional
hazards assumption was verified for each covariate using a two-sided chi-square test of the
Schoenfeld residuals.
Because missing values accounted for more than 4% of some covariates (race, prealbumin
and 24-hr urinary creatinine), we performed multiple imputations using the MICE method
[28], with 20 iterations of 20 imputations. Characteristics in Table 1 were used in the
Low Serum Creatine Kinase Predicts Mortality in Chronic Kidney Disease
PLOS ONE | DOI:10.1371/journal.pone.0156433 June 1, 2016 4 / 12
Table 1. Clinical and laboratory characteristics at baseline by gender-specific tertile of sCK level.
Characteristic All sCK level (gender speciﬁc tertile) p Missing data n (%)
1st (lowest) 2th 3th (highest)
Total 1801 610 (34) 596 (33) 595 (33)
Age (years) 61 (48–71) 64 (52–73) 61 (47–71) 58 (48–69) < 0.001 0
Male n (%): 1214 (67) 410 (67) 404 (68) 400 (67) 1 0
Female n (%) 587 (33) 200 (33) 192 (32) 195 (33)
Ethnicity n (%): African origin 224 (13) 11 (2) 44 (8) 169 (30) < 0.001 81 (4)
Ethnicity n (%): Other 1496 (87) 570 (98) 525 (92) 401 (70)
Cardiovascular disease n (%): Yes 321 (18) 119 (20) 103 (18) 99 (17) 0.4 37 (2)
Cardiovascular disease n (%): No 1443 (82) 481 (81) 481 (82) 481 (83)
Diabetesa n (%): Yes 490 (27) 155 (26) 147 (25) 188 (32) 0.01 6 (0.3)
Diabetesa n (%): No 1305 (73) 451 (74) 448 (75) 406 (68)
Smoking n (%): Non smoker 965 (54) 273 (45) 331 (56) 361 (61) < 0.001 0
Smoking n (%): Present or past smoker 836 (46) 337 (55) 265 (44) 234 (40)
BMI < 19 kg/m2 61 (3) 28 (5) 24 (4) 9 (2) < 0.001 0
BMI: 19–25 kg/m2 684 (38) 267 (44) 234 (39) 183 (31)
BMI: 25–30 kg/m2 674 (37) 209 (34) 219 (37) 246 (41)
BMI > 30 kg/m2 382 (21) 106 (17) 119 (20) 157 (26)
Systolic BP (mmHg) 133 (121–147) 133 (121–148) 131 (120–145) 135 (123–148) 0.04 59 (3)
Diastolic BP (mmHg) 74 (67–82) 74 (66–81) 73 (67–81) 75 (68–83) 0.01 59 (3)
Antihypertensive medication n (%): Yes 1586 (92) 518 (89) 523 (91) 545 (95) 0.004 76 (4)
Antihypertensive medication n (%): No 139 (8) 62 (11) 46 (8) 31 (5)
Statin use n (%): Yes 787 (46) 245 (42) 254 (44) 288 (50) 0.03 76 (4)
Statin use n (%): No 938 (54) 335 (58) 315 (55) 288 (50)
Serum creatinine (μmol/l) 145 (112–190) 143 (110–188) 142 (109–119) 152 (118–198) 0.005 0
mGFR (ml/min) 40 (29–55) 38 (28–54) 42 (29–55) 41 (30–55) 0.08 0
eGFR (CKD-Epi) 42 (30–58) 41 (30–58) 53 (31–58) 41 (30–57) 0.4 0
PCR (mg/kg) 26 (12–89) 26 (12–80) 23 (11–78) 28 (12–117) 0.3 78 (4)
Albumin (g/l) 40 (37–42) 39 (37–42) 40 (37–42) 40 (37–42) 0.05 43 (2)
Prealbumin (g/l) 0.30 (0.26–0.35) 0.30 (0.26–0.35) 0.30 (0.26–0.35) 0.31 (0.27–0.35) 0.1 384 (21)
ASAT (UI/l) 24 (19–29) 21 (17–26) 24 (19–28) 27 (22–33) < 0.001 8 (0.4)
HDL-cholesterol (g/l) 1.23 (1.00–1.54) 1.21 (0.96–1.53) 1.25 (1.02–1.56) 1.22 (1.02–1.54) 0.4 71 (4)
UCr (mmol/24h) 12 (9–15) 10.9 (8.8–13.2) 11.7 (9.6–14.2) 12.9 (10.3–15.9) < 0.001 209 (12)
Nephropathy: PKD 106 (6) 36 (6) 38 (6) 32 (5) < 0.001 0
Nephropathy: Diabetic 178 (10) 42 (7) 49 (8) 87 (15)
Nephropathy: Glomerular 259 (14) 84 (14) 92 (15) 83 (14)
Nephropathy: Interstitial 164 (9) 65 (11) 52 (9) 47 (8)
Nephropathy: Vascular 464 (26) 161 (26) 151 (25) 152 (26)
Nephropathy: Other / Undetermined 630 (35) 222 (36) 214 (36) 194 (33)
CV, cardiovascular; BMI, body mass index; BP, blood pressure; mGFR, measured glomerular ﬁltration rate; PCR, proteinuria/creatinuria ratio; ASAT:
Aspartate transaminase, normal range < 35UI/l; Albumin normal range 38–48 g/l; Prealbumin normal range 0.18–0.38 g/l; HDL-cholesterol normal
range > 1 mmol/L. PKD: polycystic kidney disease. Results expressed as n (%) for qualitative variables and median (IQR, interquartile range) for
quantitative variables.
a Fasting glucose  7 mmol/L or HbA1c  6.5 or antidiabetic treatment or reported diabetes.
Statistical analyses were performed using R version 3.2.2 software (R Development Core Team, 2005).
doi:10.1371/journal.pone.0156433.t001
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imputation model, as well as used in survival status and time to the censoring event. Missing
values for follow-up visits were replaced by the most recent available values. Imputed data sets
were analyzed with previously described multivariate Cox survival models, and analysis results
were pooled using Rubin and Schencker’s rules [29].
Ethics statement
All patients gave written informed consent before inclusion in the study. The NephroTest
study design was approved by an ethics committee (Direction générale pour la recherche et
l’innovation. Comité consultatif sur le traitement de l’information en matière de recherche
dans le domaine de la santé (CCTIRS). Réf: DGRI CCTIRS MG/CP09.503, 9th July 2009).
Results
Patient Characteristics at baseline and associations with sCK levels
In the study, 1801 individuals were included, and the median baseline sCK level was 122
(IQR = 80–181) UI/L; the median age of participants at inclusion was 61 (48–71) years, and
most of the patients were male (67%) (Table 1). Twenty-seven percent of the patients were dia-
betic. The median mGFR was 40 (29–55) ml/min. Taken as a continuous variable, sCK levels
were higher in men (133 (91–199) UI/L in men vs 98 (67–145) in women, p<0.001). Normal
laboratory ranges of sCK are different in men and women, and establishing sCK thresholds for
high or low values requires differentiating men from women. We therefore used gender-spe-
cific tertiles to study sCK, with cutoff points of 106 and 171 UI/l in men and 76 and 124 UI/l in
women. A higher sCK tertile was significantly associated with a lower age (p<0.001), high 24-h
UCr (p<0.001), and high BMI (p<0.001) but not with mGFR or eGFR. As expected, statin use
at inclusion was associated with a higher sCK level (p = 0.03). sCK levels were higher in
patients with diabetes and diabetic nephropathy (S1 Table).
Mortality and ESRD risk according to baseline sCK level
Over a median follow-up period of 6.0 years (3.6–8.5), 327 (18%) patients died including 221
(12%) before ESRD, and 377 (21%) patients reached ESRD. Patient overall survival and pre-
ESRD survival were significantly lower in patients with the lowest baseline sCK level (Fig 2A
and 2B). Indeed, patients in the lowest gender-specific sCK tertile had a crude higher risk of
death (Hazard Ratio (HR) of 1.77, 95% CI (1.35–2.32) compared to the highest sCK tertile).
The lowest sCK tertile was consistently associated with the highest risk of death after adjust-
ment for covariates (Table 2 and S2 Table). In the fully adjusted model (model 5a), using the
third (highest) gender-specific sCK tertile as reference HR, the adjusted HR for death (95% CI)
was 1.37 (1.02–1.86) for the lowest sCK tertile. In addition to baseline sCK levels, several covar-
iates were independent risk factors for death: age (p<0.001), measured GFR (p<0.001), history
of cardiovascular disease (p<0.001), serum albumin (p = 0.04) and prealbumin (p = 0.008),
smoking status (p = 0.006) and proteinuria (p = 0.002) (Table 3). Similar results were obtained
using pre-ESRD mortality as end-point (S3 Table).
The Kaplan-Meier curve indicates that the incidence of ESRD is comparable between the
three sCK tertiles, and the crude HR (95% IC) is 0.98 (0.76–1.26), 1.01 (0.79–1.29) and 1 for
the 1st, 2nd and 3rd tertiles, respectively (Fig 2C).
Mortality risk associated with sCK levels over time
Given that sCK may fluctuate over time, we used a time-dependent Cox model to evaluate the
crude and adjusted HRs (Table 4 and S4 Table) of mortality associated with sCK levels at each
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patient visit. In the crude model, mortality risk was significantly higher in the lowest gender-
specific sCK tertile compared with the third (highest) sCK tertile: HR (95% IC) 2.13 (1.63–
2.77). These results were similar in the different adjusted models; in the fully adjusted model
(model 5a), using the third (highest) gender-specific sCK tertile as a reference HR, the adjusted
HR for death (95% CI) was 2.17 (1.51–3.12) for the lowest sCK tertile.
Discussion
Our results indicate that the sCK level is an independent predictor of mortality but not ESRD
in patients with CKD. Furthermore, our data support the hypothesis that the sCK level can be
used as a proxy for muscle mass evaluation.
We excluded 12 patients with an sCK level higher than five times the normal level, as this is
the usual biologic threshold for sCK levels to support rhabdomyolysis. High sCK levels at base-
line were not associated with ESRD risk, suggesting that moderately elevated sCK might not be
accompanied by renal tubular toxicity and incident renal failure that can occur upon
rhabdomyolysis.
Table 2. Crude and fully-adjusted HRs (95%CI) of death according to baseline gender-specific sCK
tertiles. The highest gender-specific sCK tertile is taken as the reference tertile.
gender-speciﬁc sCK tertile
1st (lowest) 2nd 3rd (highest)
Events 142 103 82
Crude 1.77 (1.35–2.32) 1.19 (0.89–1.59) 1
Model 5a 1.37 (1.02–1.86) 1.11 (0.82–1.51) 1
Model 5a: crude + age, gender, ethnicity, center, statin intake, ASAT, measured GFR, history of
cardiovascular disease, diabetes, smoking status, systolic blood pressure, type of nephropathy, logarithm
of proteinuria/creatinuria ratio, serum albumin, prealbumin, BMI, 24-h urinary creatinine excretion.
doi:10.1371/journal.pone.0156433.t002
Fig 2. Kaplan-Meier patient survival curves according to gender-specific sCK tertiles. Kaplan-Meier patient overall survival curve according to
gender-specific sCK tertiles. Log-rank test: p<0.001. Fig 2B. Kaplan-Meier pre-ESRD patient survival curve according to gender-specific sCK tertiles.
Log-rank test: p<0.001. Fig 2C. Kaplan-Meier renal survival curve according to gender-specific sCK tertiles. Log-rank test: p = 0.9.
doi:10.1371/journal.pone.0156433.g002
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Rather, we showed that low sCK levels, both at baseline and over the follow-up period, were
significantly associated with mortality in CKD patients, independent of confounding factors.
This led us to conclude that sCK is an independent and strong risk factor of mortality among
CKD patients.
Table 3. Multivariate adjusteda HRs (95%CI) of baseline covariates for death.
Risk factor Mortality HR (95% CI)
Gender-speciﬁc sCK level
1st tertile (lowest) 1.37 (1.02–1.86)
2nd tertile 1.11 (0.82–1.51)
3rd tertile (highest) 1
Age, per year greater 1.05 (1.04–1.07)
Women versus men 0.73 (0.52–1.01)
African origin versus other 0.75 (0.43–1.28)
Statin use 0.97 (0.77–1.24)
ASAT, per 1 UI/l 1.01 (1.00–1.02)
mGFR at baseline, per 1 ml/min decrease 1.02 (1.01–1.03)
History of CV disease 1.79 (1.40–2.30)
Diabetesb 1.17 (0.87–1.56)
Present or past smoker versus non smoker 1.39 (1.10–1.77)
Systolic BP, per 10 mmHg greater 1.00 (0.99–1.00)
Logarithm of PCR 1.17 (1.06–1.30)
Nephropathy
PKD 1
Diabetic 1.59 (0.74–3.42)
Glomerular 0.60 (0.26–1.36)
Interstitial 0.79 (0.35–1.77)
Vascular 1.38 (0.69–2.77)
Other / Undetermined 1.39 (1.09–1.77)
Prealbumin,  0.3 versus > 0.3 g/L 1.44 (1.10–1.88)
24-h urinary creatinine excretion, per mmol/24 h 0.98 (0.94–1.02)
CV, cardiovascular; BMI, body mass index; BP, blood pressure; mGFR, measured glomerular ﬁltration rate;
eGFR, estimated glomerular ﬁltration rate; PCR, proteinuria/creatinuria ratio. PKD, polycystic kidney
disease. 24-h urinary creatinine excretion is expressed as gender-speciﬁc quartiles.
a Including adjustment for center.
b Fasting glucose  7 mmol/L or HbA1c  6.5 or antidiabetic treatment or reported diabetes
doi:10.1371/journal.pone.0156433.t003
Table 4. Crude and fully-adjusted HRs (95%CI) of death according to time-dependent gender-specific
sCK tertiles.
1st (lowest) 2th 3th (highest)
Crude 2.13 (1.63–2.77) 1.09 (0.80–1.48) 1
Model 5a 1.74 (1.31–2.32) 1.00 (0.73–1.37) 1
Model 5a: crude + age, gender, ethnicity, center, statin intake, ASAT, measured GFR, history of
cardiovascular disease, diabetes, smoking status, systolic blood pressure, type of nephropathy, logarithm
of proteinuria/creatinuria ratio, serum albumin, prealbumin, BMI, 24-h urinary creatinine excretion.
doi:10.1371/journal.pone.0156433.t004
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Because sCK levels were positively correlated with numerous parameters that more or less
directly reflect muscle mass, including younger age, BMI, ethnicity, and UCr, a known marker
of muscle mass [30], we propose that sCK levels reflect muscle mass and that patients with low
muscle mass and a low sCK level experience higher mortality rates. Indeed, nutritional status,
including catabolic versus anabolic rates, is a strong predictor of all-cause mortality [31]. Sup-
porting the link between sCK and muscle mass, clinical data indicate that sCK activity is related
to lean body mass [21] and that sCK levels at rest are higher in athletes compared to sedentary
subjects, possibly due to the regular training athletes undergo [32,33], and, consequently, result
in increased anabolism [19,34]. Another possible explanation for these results is that sCK level
reflects physical activity beyond its impact on muscle mass. Indeed, intense or prolonged physi-
cal activity is associated with a physiological elevation of sCK levels [35,36]. Participants were
not asked to rest prior to blood sampling, and we cannot exclude that sCK levels can be influ-
enced by recent physical activity, at least in some individuals. Notably, physical inactivity has
been associated with mortality in both CKD and non-CKD populations [37].
We also found a significant association between sCK levels and nutritional markers such as
BMI, serum albumin and prealbumin, but this association was not as strong as with UCr. In
fact, the median serum albumin and prealbumin values were almost equal in all sCK tertiles. It
is therefore likely that sCK is a better predictor of muscle mass than serum albumin and preal-
bumin. Furthermore, serum albumin is difficult to interpret in the context of nephropathy due
to albumin urinary loss. sCK was also positively associated with serum creatinine. Serum creat-
inine is increased in the presence of renal failure but is also a marker of muscle mass [38],
which could explain this correlation.
Notably, we are unable to provide direct markers of muscle mass to confirm the role of sCK
as a biomarker for muscle mass. The strong correlation of sCK to surrogate markers, such as
creatinine and UCr, as well as converging data in the literature, is, however, very suggestive of a
strong association between sCK and muscle mass.
This study only included pre-ESRD CKD patients with a median GFR of 40 ml/min.
Although sCK levels have been reported to be associated with nutrition status and muscle mass
in non-CKD populations, no study has shown, to this date, a relationship between sCK levels
and mortality in the general population. The impact of low sCK levels might therefore differ in
other populations.
In conclusion, this study is the first to establish the role of sCK as an independent predictor
of mortality in a CKD population. Our results indicate that sCK might reflect nutritional status,
and could also be used as a biomarker for muscle mass gain or loss in this population.
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